Ando, H., Yoshinaga, T., Yamamoto, W., Asakura, K., Uda, T., Taniguchi, T., Ojima, A., Shinkyo, R., Kikuchi, K., Osada, T., Hayashi, S., Kasai, C., Miyamoto, N., Tashibu, H., Yamazaki, D., Sugiyama,
A., Kanda, Y., Sawada, K., Sekino, Y. (2017): A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods. 84, 111-127.
Azizi, M., Chedid, A. and Oudard, S. (2008): Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 358, 95-7.
Bair, S.M., Choueiri, T.K. and Moslehi, J. (2013): Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends. Cardiovasc. Med. 23,104-113.
Baroletti, S., Catella, J., Ehle, M., Cheng, J.W. (2010): Dronedarone: a review of characteristics and clinical data. Crit. Pathw. Cardiol. 9, 94-101.
Bicer, S., Patchell, J.S., Hamlin, D.M., Hamlin, R.L. (2002): Acute effects of escalating doses of amiodarone in isolated guinea pig hearts. J. Vet. Pharmacol. Ther. 25, 221-226.
Blinova, K., Stohlman, J., Vicente, J., Chan, D., Johannesen, L., Hortigon-Vinagre, M.P., Zamora, V., Smith, G., Crumb, W.J., Pang, L., Lyn-Cook, B., Ross, J., Brock, M., Chvatal, S., Millard, D., Galeotti, L., Stockbridge, N., Strauss, D.G. (2017): Comprehensive Translational Assessment of HumanInduced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol. Sci. 155, 234-247
Bogdan, R., Goegelein, H., Ruetten, H. (2011): Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn Schmiedebergs Arch. Pharmacol. 383, 347-356.
Britten, C.D., Kabbinavar, F., Hecht, J.R., Bello, C.L., Li, J., Baum, C. and Slamon, D. (2008): A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 61, 515-24.
Chen, H.X. and Cleck, J.N. (2009): Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6, 465-477.
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., Pangalos, M.N. (2014): Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug. Discov. 13, 419-431.
Crumb, W.J. Jr, Vicente, J., Johannesen, L., Strauss, D.G. (2016): An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J. Pharmacol. Toxicol. Methods. 81, 251-262.
Curwen, J.O., Musgrove, H.L., Kendrew, J., Richmond, G.H., Ogilvie, D.J. and Wedge, S.R. (2008): Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin. Cancer Res. 14, 3124-31.
Denning. C., Borgdorff, V., Crutchley, J., Firth, K.S., George, V., Kalra, S., Kondrashov, A., Hoang, M.D., Mosqueira, D., Patel, A., Prodanov, L., Rajamohan, D., Skarnes, W.C., Smith, J.G., Young, L.E. (2016): Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim. Biophys. Acta. 1863, 1728-1748.
Drevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J., Jürgensmeier, J.M., Puchalski, T.A., Young, H., Saunders, O. and Unger, C. (2007): Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25, 3045-54.
Facemire, C.S., Nixon, A.B., Griffiths, R., Hurwitz, H. and Coffman, T.M. (2009): Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 54, 652-8.
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., Armand, J.P., Scigalla, P. and Raymond, E. (2006): Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25-35.
Ferrara, N. (2004): Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581–611.
Ferrara, N., Gerber, H.P. and LeCouter, J. (2003): The biology of VEGF and its receptors. Nature Med.9, 669-676.
Fountzilas, G., Fragkoulidi, A., Kalogera-Fountzila, A., Nikolaidou, M., Bobos, M., Calderaro, J., Andreiuolo, F. and Marselos, M. (2010): A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother. Pharmacol. 65, 649-60.
Franklin, P.H., Banfor, P.N., Tapang, P., Segreti, J.A., Widomski, D.L., Larson, K.J., Noonan, W.T.,
Gintant, G.A., Davidsen, S.K., Albert, D.H., Fryer, R.M. and Cox, B.F. (2009): Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)- N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: Reversal with antihypertensive agents and effect on tumor growth inhibition. J. Pharmacol. Exp. Ther. 329, 928-37.
Frohnwieser, B., Chen, L.Q., Schreibmayer, W., Kallen, R.G. (1997): Modulation of the human cardiac sodium channel alpha-subunit by cAMP-dependent protein kinase and the responsible sequence domain. J. Physiol. 498, 309-318.
Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S. and Nakajima, K. (2008): Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 99, 159-65.
Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O., Popescu, L.M. (2011): Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. J. Cell. Mol. Med. 15, 2539-2551.
Goineau, S., Castagné, V., Guillaume, P., Froget, G. (2012): The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects. J. Pharmacol. Toxicol. Methods. 66, 52-58.
Gottfridsson, C., Panfilov, S., Ebrahimi, A., Gigger, E., Pollard, C., Henderson, S., Ambery, P.,Raichlen, J.S. (2016): Drug-induced blood pressure increase – recommendations for assessment in clinical and non-clinical studies. Expert Opin. Drug Saf. 16, 215-225.
Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., Kolaja,K. L. (2011): Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
Guo, L., Dong, Z., Guthrie, H. (2009): Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods. 60,130-151.
Guth, B.D., Chiang, A.Y., Doyle, J., Engwall, M.J., Guillon, J.M., Hoffmann, P., Koerner, J., Mittelstadt, S., Ottinger, S., Pierson, J.B., Pugsley, M.K., Rossman, E.I., Walisser, J., Sarazan, R.D. (2015): The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESIsponsored consortium. J. Pharmacol. Toxicol. Methods. 75, 70-90.
Hamlin, R.L., Cruze, C.A., Mittelstadt, S.W., Kijtawornrat, A., Keene, B.W., Roche, B.M., Nakayama, T., Nakayama, H., Hamlin, D.M., Arnold, T. (2004): Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J. Pharmacol. Toxicol. Methods. 49, 15-23.
Harris K., Aylott M., Cui Y., Louttit J.B., McMahon N.C., Sridhar A. (2013): Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134, 412-426.
Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J., Furukawa, T. (2014): Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J. Mol. Cell. Cardiol. 77, 178-191.
Hayakawa, T., Kunihiro, T., Dowaki, S., Uno, H., Matsui, E., Uchida, M., Kobayashi, S., Yasuda, A., Shimizu, T., Okano, T. (2012): Noninvasive evaluation of contractile behavior of cardiomyocyte monolayers based on motion vector analysis. Tissue. Eng. Part. C. Methods. 18, 21-32.
Hoehns J.D., Stanford, R.H., Geraets, D.R., Skelly, K.S., Lee, H.C., Gaul, B.L. (2001): Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy. 21, 871-883.
Honda, M., Kiyokawa, J., Tabo, M., Inoue, T. (2011): Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J. Pharmacol. Sci. 117, 149-159.
Honda, M., Komatsu, R., Holzgrefe, H.H., Yamada, Y., Isobe, T., Kimura, K., Itoh, T., Tamaoki, N., Tabo, M. (2010): Application of probabilistic analysis for precisely correcting the QT interval for heart rate in telemetered common marmosets. J. Pharmacol. Toxicol. Methods. 61, 264-270.
Horowitz, J.R., Rivard, A., van der Zee, R., Hariawala, M., Sheriff, D.D., Esakof, D.D., Chaudhry, G.M., Symes, J.F. and Isner, J.M. (1997): Vascular endothelial growth factor/vascular permeability factor produces nitric oxide–dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb. Vasc. Biol. 17, 2793-800. ICH Harmonised Tripartite Guideline, Safety Pharmacology Studies For Human Pharmaceuticals (S7A). Recommended for Adoption at Step 4 of the ICH Process on 8 November 2000 by the ICH Steering Committee.
Isobe, T., Komatsu, R., Honda, M., Kuramoto, S., Shindoh, H., Tabo, M. (2014): Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats. J. Toxicol. Sci. 39, 237-242.
Isobe, T., Honda, M., Komatsu, R., Tabo, M. (2018): Conduction and contraction properties of human iPS cell-derived cardiomyocytes: analysis by motion field imaging compared with the guinea-pig isolated heart model. J. Toxicol. Sci. 43, 493-506.
Isobe, T., Honda, M., Komatsu, R., Tabo, M. (2019): Cardiac safety assessment with motion field imaging analysis of human iPS cell-derived cardiomyocytes is improved by an integrated evaluation with cardiac ion channel profiling. J. Toxicol. Sci. 44, 859-870.
Izumi-Nakaseko, H., Nakamura, Y., Wada, T., Ando, K., Kanda, Y., Sekino, Y., Sugiyama, A. (2017): Characterization of human iPS cell-derived cardiomyocyte sheets as a model to detect drug-induced conduction disturbance. J. Toxicol. Sci. 42, 183-192.
Kadota, S., Minami, I., Morone, N., Heuser, J.E., Agladze, K., Nakatsuji, N. (2013): Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur. Heart. J. 34, 1147-1156.
Kamp, T.J. and Hell, J.W. (2000): Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ. Res. 87, 1095-1102.
Kane, C., Couch, L., Terracciano, C.M. (2015): Excitation-contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes. Front. Cell. Dev. Biol. 3:59.
Kappers, M.H., van Esch, J.H., Sluiter, W., Sleijfer, S., Danser, A.H. and van den Meiracker, A.H. (2010): Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 56, 675-81.
Katritsis D., Morgan J., Brachmann J., Bygrave A., O'Farrell D., Rowland E., Camm A.J. (1997): Electrophysiological effects of E 4031, a drug with selective class III properties, in man. Pacing Clin. Electrophysiol. 20, 930-937.
Kerbel, R.S. (2008): Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049.
Kitaguchi, T., Moriyama, Y., Taniguchi, T., Maeda, S., Ando, H., Uda, T., Otabe, K., Oguchi, M., Shimizu, S., Saito, H., Toratani, A., Asayama, M., Yamamoto, W., Matsumoto, E., Saji, D., Ohnaka, H., Miyamoto, N. (2017): CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods. 85, 73-81.
Kitaguchi, T., Moriyama, Y., Taniguchi, T., Ojima, A., Ando, H., Uda, T., Otabe, K., Oguchi, M., Shimizu, S., Saito, H., Morita, M., Toratani, A., Asayama, M., Yamamoto, W., Matsumoto, E., Saji,
D., Ohnaka, H., Tanaka, K., Washio, I., Miyamoto, N. (2016): CSAHi study: Evaluation of multielectrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities. J. Pharmacol. Toxicol. Methods. 78, 93-102.
Komatsu, R., Honda, M., Holzgrefe, H.H., Kubo, J., Yamada, Y., Isobe, T., Kimura, K., Itoh, T., Tamaoki, N., Tabo, M. (2010): Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study. J. Pharmacol. Toxicol. Methods. 61, 271-276.
Kopljar, I., De Bondt, A., Vinken, P., Teisman, A., Damiano, B., Goeminne, N., Van den Wyngaert, I., Gallacher, D.J, Lu, H.R. (2017): Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes. Br. J. Pharmacol. 174, 3766-3779.
Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S., Brown, A.M. (2013): MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 3, 2100.
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., Pirmohamed, M., Pollard, C., Radford, J., Roome, N., Sager, P.,Singh, S., Suter, T., Suter, W., Trafford, A., Volders, P., Wallis, R., Weaver, R., York, M., Valentin, J.(2011): How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-693.
Le Tourneau, C., Raymond, E. and Faivre, S. (2007): Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther. Clin. Risk Manag. 3, 341-8.
Li M., Kanda, Y., Ashihara, T., Sasano, T., Nakai Y, Kodama, M., Hayashi, E., Sekino, Y., Furukawa, T., Kurokawa, J. (2017): Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs. J. Pharmacol. Sci. 134, 75-85.
Lu, H.R., Rohrbacher, J., Vlaminckx, E., Van, Ammel, K., Yan, G.X., Gallacher, D.J. (2010): Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers. Br. J. Pharmacol. 160, 60-76.
Lu, H.R., Whittaker, R., Price, J.H., Vega, R., Pfeiffer, E.R., Cerignoli, F., Towart, R., Gallacher, D.J. (2015): High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a
Large Panel of Cardioactive and Inactive Compounds. Toxicol. Sci. 148, 503-516.
Ma. J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja, K.L., Swanson, B.J., January, C.T. (2011): High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017.
Maitland, M.L., Kasza, K.E., Karrison, T., Moshier, K., Sit, L., Black, H.R., Undevia, S.D., Stadler, W.M., Elliott, W.J. and Ratain, M.J. (2009): Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 15, 6250-7.
Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, L.J., Carver, J., Chan, E., Moss, K.G., Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G. and Cherrington, J.M. (2003):
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-37.
Minami, H., Kawada, K., Ebi, H., Kitagawa, K., Kim, Y.I., Araki, K., Mukai, H., Tahara, M., Nakajima, H. and Nakajima, K. (2008): Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 99, 1492-8.
Nozaki, Y., Honda, Y., Watanabe, H., Saiki, S., Koyabu, K., Itoh, T., Nagasawa, C., Nakamori, C.,
Nakayama, C., Iwasaki, H., Suzuki, S., Washio, I., Takahashi, E., Miyamoto, K., Yamanishi, A., Endo, H., Shinozaki, J., Nogawa, H., Kunimatsu, T. (2016): CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol. 77, 75-86.
Park S.I., An H., Kim A., Jang I.J., Yu K.S., Chung J.Y. (2016): An analysis of QTc prolongation with atypical antipsychotic medications and selective serotonin reuptake inhibitors using a large ECG record database. Expert Opin. Drug Saf. 8, 1013-1019.
Paul, A.A., Witchel, H.J., Hancox, J.C. (2002): Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. 136, 717-729.
Pointon, A., Harmer, A.R., Dale, I.L., Abi-Gerges, N., Bowes, J., Pollard, C., Garside, H. (2015): Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 144, 227-237.
Rao, C., Prodromakis, T., Kolker, L., Chaudhry, U.A., Trantidou, T., Sridhar, A., Weekes, C., Camelliti, P., Harding, S.E., Darzi, A., Yacoub, M.H., Athanasiou, T., Terracciano, C.M. (2013): The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials. 34, 2399-2411.
Robinson, E.S., Khankin, E.V., Choueiri, T.K., Dhawan, M.S., Rogers, M.J., Karumanchi, S.A. and Humphreys, B.D. (2010b): Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor–signaling inhibitors. Hypertension. 56, 1131-6.
Robinson, E.S., Matulonis, U.A., Ivy, P., Berlin, S.T., Tyburski, K., Penson, R.T. and Humphreys, B.D. (2010a): Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin. J. Am. Soc. Nephrol. 5, 477-83.
Ryan, C.J., Stadler, W.M., Roth, B., Hutcheon, D., Conry, S., Puchalski, T., Morris, C. and Small, E.J. (2007): Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest. New Drugs 25, 445-51.
Sakakibara, Y., Furukawa, T., Singer, D.H., Jia, H., Backer, C.L., Arentzen, C.E., Wasserstrom, J.A. (1993): Sodium current in isolated human ventricular myocytes. Am J Physiol. 265, H1301-H1309.
Salameh, A., Krautblatter, S., Karl, S., Blanke, K., Gomez, D.R., Dhein, S., Pfeiffer, D., Janousek, J. (2009): The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors. Br. J. Pharmacol. 158, 198-208.
Skinner, M., Philp, K., Lengel, D., Coverley, L., Lamm Bergström, E., Glaves, P., Musgrove, H., Prior, H., Braddock, M., Huby, R., Curwen, J.O., Duffy, P., Harmer, A.R. (2016): The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br. J. Pharmacol. 171, 2308-2320.
Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., Hirte, H.W., Eder, J.P., Lenz, H.J. and Schwartz, B. (2007): Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12, 426-37.
Sugano, S., Tsubone, H., Nakata, Y., Morita, H., Kuwahara, M., Kobayashi, T., Katsuta, S., Uchino, T., Satoh, K., Fukusaki, K., Iwase, M., Kanai, T. and Miyashima, H. (2003): Electrocardiogram, echocardiogram, blood pressure and pathological examination of animals for basic and clinical science. (Sugano, S., Tsubone, H. and Nakata, Y.), pp.124, Adthree Publishing Co., Ltd., Tokyo.
Tabo, M., Komatsu, R., Isobe, T., Honda, M., Yamada, Y., Kimura, K. (2010): Accurate detection of drug-induced delayed ventricular repolarization with a suitable correction formula in Langendorff guinea pig heart. J. Toxicol. Sci. 35, 687-698.
Takasuna, K., Asakura, K., Araki, S., Ando, H., Kazusa, K., Kitaguchi, T., Kunimatsu, T., Suzuki, S., Miyamoto, N. (2017): Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative. J. Pharmacol. Toxicol. Methods. 83, 42-54.
Tolcher, A.W., Appleman, L.J., Shapiro, G.I., Mita, A.C., Cihon, F., Mazzu, A. and Sundaresan, P.R. (2011): A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 67, 751-64.
US Food and Drug Administration (2008). Pharmacology Review(s) of NDA: 22-425.
Vandenberg, J.I., Varghese, A., Lu, Y., Bursill, J.A., Mahaut-Smith, M.P., Huang, C.L. (2006): Temperature dependence of human ether-a-go-go-related gene K+ currents. Am. J. Physiol. Cell. Physiol. 291, C165-175.
Wedge, S.R., Kendrew, J., Hennequin, L.F., Valentine, P.J., Barry, S.T., Brave, S.R., Smith, N.R.,James, N.H., Dukes, M., Curwen, J.O., Chester, R., Jackson, J.A., Boffey, S.J., Kilburn, L.L., Barnett, S., Richmond, G.H., Wadsworth, P.F., Walker, M., Bigley, A.L., Taylor, S.T., Cooper, L., Beck, S., Jürgensmeier, J.M. and Ogilvie, D.J. (2005): AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-400.
Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L.E., Bollag, G. and Trail, P.A. (2004): BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-109.
Wu, S., Chen, J.J., Kudelka, A., Lu, J. and Zhu, X. (2008): Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9, 117-23.
Yamamoto, W., Asakura, K., Ando, H., Taniguchi, T., Ojima, A., Uda, T., Osada, T., Hayashi, S., Kasai, C., Miyamoto, N., Tashibu, H., Yoshinaga, T., Yamazaki, D., Sugiyama, A., Kanda, Y., Sawada, K., Sekino, Y. (2016): Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential. PLoS One. 11, e0167348.
Yamamoto, N., Tamura, T., Yamamoto, N., Yamada, K., Yamada, Y., Nokihara, H., Fujiwara, Y., Takahashi, T., Murakami, H., Boku, N., Yamazaki, K., Puchalski, T.A. and Shin, E. (2009): Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 64, 1165-72.
Yu, T. and Niu, T. (2014): Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency. Can. Fam. Physician 60, 1012–1015.
Zeng, H., Wang, J., Clouse, H., Lagrutta, A., Sannajust, F. (2019): Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on In Vitro Cardiac Safety Evaluation. Toxicol Sci. 167, 573-580.
Zhang, X.H., Haviland, S., Wei, H., Sarić, T., Fatima, A., Hescheler, J., Cleemann, L., Morad, M. (2013): Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell. Calcium. 54, 57-70.
Zhu, X., Stergiopoulos, K. and Wu, S. (2009): Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta. Oncol. 48, 9-17.
Zicha, S., Moss, I., Allen, B., Varro, A., Papp, J., Dumaine, R., Antzelevich, C., Nattel, S. (2003): Molecular basis of species-specific expression of repolarizing K+ currents in the heart. Am. J. Physiol. Heart Circ. Physiol. 285, H1641-H1649.
論文の公開元へ
